$1.43
-3.5%Lite Strategy, Inc. a clinical-stage pharmaceutical company, focuses on the development of novel and differentiated therapies for the treatment of cancer. The company was formerly known as MEI Pharma, Inc. and changed its name to Lite Strategy, Inc. in September 2025. Lite Strategy, Inc. was incorporated in 2000 and is based in San Diego, California.
Excellent liquidity position. The company can easily cover its short-term obligations with substantial cushion.
Conservative capital structure. The company relies primarily on equity financing, indicating low financial risk.
Strong working capital position provides significant operational flexibility and financial cushion.
Asset-light business model with high liquidity. Majority of assets are easily convertible to cash.
Strong financial foundation: Excellent liquidity combined with conservative leverage suggests the company is well-positioned to weather economic uncertainties and fund growth opportunities.
LITS • NASDAQ
| Lite Strategy, Inc. Balance Sheet | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|
ASSETS | |||||
CURRENT ASSETS | |||||
18M | 3.7M | 16.9M | 15.7M | 8.5M | |
0.0 | 34.6M | 83.8M | 137.5M | 144.9M | |
18M | 38.3M | 100.7M | 153.3M | 153.4M | |
0.0 | 0.0 | 85K | 10M | 7.6M | |
0.0 | 0.0 | 0.0 | 0.0 | 7.6M | |
0.0 | 0.0 | 85K | 10M | 0.0 | |
215K | 1.1M | 4.6M | 3.8M | 0.0 | |
59K | 1.4M | 2.2M | 0.0 | 3.8M | |
18.3M | 40.8M | 107.5M | 167.1M | 164.8M | |
NON-CURRENT ASSETS | |||||
0.0 | 606K | 13.3M | 10.7M | 9.3M | |
0.0 | 606K | 13.3M | 10.7M | 9.3M | |
18.3M | 41.4M | 120.8M | 177.8M | 174.1M | |
LIABILITIES | |||||
CURRENT LIABILITIES | |||||
176K | 3.2M | 6.1M | 7.9M | 6.4M | |
176K | 3.2M | 6.1M | 7.9M | 6.4M | |
873K | 2.4M | 5.3M | 6.5M | 3.5M | |
0.0 | 0.0 | 0.0 | 0.0 | 928K | |
0.0 | 0.0 | 1.4M | 871K | 0.0 | |
0.0 | 0.0 | 317K | 4.8M | 4.5M | |
305K | 2.8M | 7.2M | 4.3M | 4.9M | |
1.4M | 8.4M | 20.3M | 24.4M | 20.2M | |
NON-CURRENT LIABILITIES | |||||
0.0 | 0.0 | 64.5M | 90.6M | 74.7M | |
0.0 | 0.0 | 0.0 | 1.6M | 22.4M | |
0.0 | 0.0 | 75.8M | 101M | 104.4M | |
0.0 | 0.0 | 12.7M | 9.6M | 7.4M | |
1.4M | 8.4M | 96.2M | 125.4M | 124.6M | |
SHAREHOLDERS' EQUITY | |||||
421.1M | 421.2M | 430.6M | 426.6M | 369.2M | |
-404.2M | -388.2M | -406M | -374.2M | -319.7M | |
16.9M | 33M | 24.6M | 52.4M | 49.5M | |
16.9M | 33M | 24.6M | 52.4M | 49.5M | |
SUMMARY | |||||
18.3M | 41.4M | 120.8M | 177.8M | 174.1M | |
0.0 | 34.6M | 83.8M | 137.5M | 144.9M | |
0.0 | 0.0 | 12.7M | 9.6M | 8.3M | |
-18M | -3.7M | -4.2M | -6.1M | -245K | |
35,655,155 | 35,655,155 | 35,655,155 | 35,655,155 | 35,655,155 |
LITS - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
8-K 8-K 2025 N/A | December 30, 2025 | December 23, 2025 | 2025 | |
DEF 14A DEF 14A 2025 N/A | December 30, 2025 | December 30, 2025 | 2025 | |
8-K 8-K 2025 N/A | December 05, 2025 | December 02, 2025 | 2025 | |
8-K/A 8-K/A 2025 (Amended) N/A | November 20, 2025 | November 14, 2025 | 2025 | |
8-K 8-K 2025 N/A | November 18, 2025 | November 14, 2025 | 2025 | |
10-Q 10-Q 2025 Q3 Q3 | November 14, 2025 | September 30, 2025 | 2025 | |
8-K 8-K 2025 N/A | October 30, 2025 | October 24, 2025 | 2025 | |
S-3 S-3 N/A | October 08, 2025 | October 08, 2025 | ||
10-K 10-K 2025 FY FY | September 26, 2025 | June 30, 2025 | 2025 | |
8-K 8-K 2025 N/A | September 15, 2025 | September 10, 2025 | 2025 |
Continue your LITS research with focused valuation guides.
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.